Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Longeveron Inc
LGVN
Healthcare
Biotechnology
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy...
adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:LGVN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 14, 2024 4:05pm
New Press Release - Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
Positive data from the Phase 2a clinical trial (CLEAR MIND ) evaluating Lomecel-B™ in Alzheimer’s disease presented in Featured Research Oral Presentation at Alzheimer’s Association International Conference® (AAIC)U.S. FDA granted Lomecel-B™ both Regenerative Medicine Advanced Therapy (RMAT...
read article.
(165)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 06, 2024 11:17am
InvestorNewsBreaks - Longeveron Inc. (NASDAQ: LGVN) Schedule
NEWS: $LGVN InvestorNewsBreaks - Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q2 2024 Financial Results, Earnings Conference CallLongeveron (NASDAQ: LGVN) , a clinical-stage, regenerative
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 05, 2024 4:05pm
New Press Release - Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report second quarter 2024 financial results...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 28, 2024 4:51pm
New Press Release - Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B(TM) in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)
– Featured Research Session oral presentation highlights findings that show Lomecel-B™ improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s Disease – – Study meets its key objectives to advance data supporting favorable benefit/risk profile...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 19, 2024 4:05pm
New Press Release - Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced the closing of its...
read article.
(65)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 18, 2024 8:59am
LGVN....Nr on P.O
done
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 18, 2024 8:45am
New Press Release - Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has entered into...
read article.
(165)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 17, 2024 10:17am
Longeveron® Announces U.S. FDA Grants Fast Track Design
News; $LGVN Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B(TM) for the Treatment of Mild Alzheimer's Disease@ FDA designation enables expedited clinical
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 17, 2024 8:00am
New Press Release - Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B(TM) for the Treatment of Mild Alzheimer's Disease
– FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ –– Second designation received for Lomecel-B™ for the treatment of mild Alzheimer’s Disease after Regenerative Medicine Advanced Therapeutics (RMAT) Designation announced on July 9, 2024...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 10, 2024 7:30am
New Press Release - Longeveron® Announces U.S. FDA Grants Lomecel-B(TM) Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease
- Lomecel-B™ appears to be the first cellular therapeutic candidate to receive RMAT designation for Alzheimer’s Disease MIAMI, July 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 09, 2024 9:00am
New Press Release - Neha Motwani Elected to Longeveron® Board of Directors
MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 08, 2024 9:00am
New Press Release - Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar, MD, Director of the Gene and Cell...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 18, 2024 4:49pm
New Press Release - Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced the closing of its...
read article.
(165)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 17, 2024 6:00pm
Longeveron® to Present at the Virtual Life Sciences Inv
News; $LGVN Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage
...more
(65)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jun 17, 2024 9:19am
LGVN.....Guess what....u've all been had.... Again!
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds 2024-06-17 05:39 ET - News Release MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >